These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 25787336)

  • 1. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
    Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
    Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword.
    Shuhendler AJ; Prasad P; Leung M; Rauth AM; Dacosta RS; Wu XY
    Adv Healthc Mater; 2012 Sep; 1(5):600-8. PubMed ID: 23184795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an Integrin α
    Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
    Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting tumors with cyclic RGD-conjugated lipid nanoparticles loaded with an IR780 NIR dye: In vitro and in vivo evaluation.
    Choi J; Rustique E; Henry M; Guidetti M; Josserand V; Sancey L; Boutet J; Coll JL
    Int J Pharm; 2017 Nov; 532(2):677-685. PubMed ID: 28279737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α
    Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
    Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RGD binding to integrin alphavbeta3 affects cell motility and adhesion in primary human breast cancer cultures.
    Georgoulis A; Havaki S; Drosos Y; Goutas N; Vlachodimitropoulos D; Aleporou-Marinou V; Kittas C; Marinos E; Kouloukoussa M
    Ultrastruct Pathol; 2012 Dec; 36(6):387-99. PubMed ID: 23181508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.
    Zhang X; Chen X
    Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.
    Zheng G; Zheng M; Yang B; Fu H; Li Y
    Biomed Pharmacother; 2019 Aug; 116():109006. PubMed ID: 31152925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent.
    Anderson CR; Hu X; Zhang H; Tlaxca J; Declèves AE; Houghtaling R; Sharma K; Lawrence M; Ferrara KW; Rychak JJ
    Invest Radiol; 2011 Apr; 46(4):215-24. PubMed ID: 21343825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problem of Diminished cRGD Surface Activity and What Can Be Done about It.
    Robitaille MC; Christodoulides JA; Liu J; Kang W; Byers JM; Raphael MP
    ACS Appl Mater Interfaces; 2020 Apr; 12(17):19337-19344. PubMed ID: 32249578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [
    Mohammadi R; Shokri B; Shamshirian D; Zarghi A; Shahhosseini S
    Daru; 2020 Jun; 28(1):87-96. PubMed ID: 31845157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
    Rangger C; Helbok A; von Guggenberg E; Sosabowski J; Radolf T; Prassl R; Andreae F; Thurner GC; Haubner R; Decristoforo C
    Int J Nanomedicine; 2012; 7():5889-900. PubMed ID: 23226020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α
    Qiu J; Cai G; Liu X; Ma D
    Biomed Pharmacother; 2017 Dec; 96():1418-1426. PubMed ID: 29079344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.
    Xiong Z; Cheng Z; Zhang X; Patel M; Wu JC; Gambhir SS; Chen X
    J Nucl Med; 2006 Jan; 47(1):130-9. PubMed ID: 16391197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells.
    Wang Y; Wang X; Zhang Y; Yang S; Wang J; Zhang X; Zhang Q
    J Drug Target; 2009 Jul; 17(6):459-67. PubMed ID: 19527117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
    Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125.
    Kim YH; Jeon J; Hong SH; Rhim WK; Lee YS; Youn H; Chung JK; Lee MC; Lee DS; Kang KW; Nam JM
    Small; 2011 Jul; 7(14):2052-60. PubMed ID: 21688390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies.
    Shi S; Zhou M; Li X; Hu M; Li C; Li M; Sheng F; Li Z; Wu G; Luo M; Cui H; Li Z; Fu R; Xiang M; Xu J; Zhang Q; Lu L
    J Control Release; 2016 Aug; 235():1-13. PubMed ID: 27235150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.